QIAGEN ROE 2010-2022 | QGEN

Current and historical return on equity (ROE) values for QIAGEN (QGEN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
QIAGEN ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $0.54B $3.24B 17.45%
2021-12-31 $0.51B $3.10B 17.15%
2021-09-30 $0.60B $3.01B 20.48%
2021-06-30 $0.48B $2.98B 16.94%
2021-03-31 $0.45B $2.85B 16.36%
2020-12-31 $0.36B $2.80B 13.56%
2020-09-30 $0.19B $2.71B 7.41%
2020-06-30 $0.01B $2.62B 0.55%
2020-03-31 $-0.03B $2.49B -1.22%
2019-12-31 $-0.04B $2.54B -1.60%
2019-09-30 $-0.03B $2.47B -0.97%
2019-06-30 $0.20B $2.63B 7.54%
2019-03-31 $0.19B $2.61B 7.31%
2018-12-31 $0.19B $2.64B 7.40%
2018-09-30 $0.09B $2.53B 3.50%
2018-06-30 $0.08B $2.52B 3.02%
2018-03-31 $0.05B $2.58B 2.12%
2017-12-31 $0.04B $2.54B 1.59%
2017-09-30 $0.09B $2.57B 3.52%
2017-06-30 $0.08B $2.51B 2.98%
2017-03-31 $0.08B $2.43B 3.21%
2016-12-31 $0.08B $2.61B 3.08%
2016-09-30 $0.12B $2.67B 4.73%
2016-06-30 $0.12B $2.63B 4.76%
2016-03-31 $0.13B $2.63B 4.96%
2015-12-31 $0.13B $2.57B 5.15%
2015-09-30 $0.10B $2.52B 4.08%
2015-06-30 $0.11B $2.54B 4.04%
2015-03-31 $0.11B $2.48B 4.26%
2014-12-31 $0.12B $2.66B 4.31%
2014-09-30 $0.15B $2.71B 5.53%
2014-06-30 $0.16B $2.76B 5.77%
2014-03-31 $0.07B $2.73B 2.68%
2013-12-31 $0.07B $2.72B 2.58%
2013-09-30 $0.05B $2.68B 1.76%
2013-06-30 $0.04B $2.60B 1.31%
2013-03-31 $0.12B $2.69B 4.46%
2012-12-31 $0.13B $2.72B 4.82%
2012-09-30 $0.09B $2.71B 3.45%
2012-06-30 $0.10B $2.64B 3.72%
2012-03-31 $0.10B $2.64B 3.74%
2011-12-31 $0.10B $2.56B 3.74%
2011-09-30 $0.13B $2.59B 5.18%
2011-06-30 $0.13B $2.59B 5.30%
2011-03-31 $0.14B $2.54B 5.69%
2010-12-31 $0.14B $2.48B 6.03%
2010-09-30 $0.15B $2.43B 6.49%
2010-06-30 $0.15B $2.34B 6.72%
2010-03-31 $0.15B $2.31B 6.98%
2009-12-31 $0.14B $2.29B 7.34%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.865B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00